Atlanta Team Develops Tool to Predict Leukemia Drug Response
Emory, Children's Healthcare of Atlanta and Georgia Tech researchers have developed GradientScreen to forecast how pediatric leukemia patients may respond to treatment.
Updated on Nov. 19, 2026 in Diseases

Researchers from Emory University, Children's Healthcare of Atlanta and Georgia Tech have developed GradientScreen, a technology that predicts how pediatric leukemia patients may respond to drug treatment at diagnosis. The approach tests drug combinations on a patient's own leukemia cells from a single blood or bone marrow sample.
Why it matters
Clinicians currently have no reliable way to know how specific drug combinations and dosages will affect a patient or whether a treatment will succeed. Acute lymphoblastic leukemia accounts for 75% of pediatric leukemia diagnoses, so a tool that anticipates treatment response could shape care for a large share of young patients in Atlanta and beyond.
The evidence is a retrospective study of 17 leukemia cell and bone marrow samples from acute lymphoblastic leukemia patients, with results compared against residual disease after induction and relapse status. The study does not yet show how the tool performs when used prospectively on new patients, and its accuracy in a larger population remains unknown.
The players
Emory University
Emory University is a private research university in Atlanta, Georgia, whose researchers led the development of GradientScreen.
Children's Healthcare of Atlanta
Children's Healthcare of Atlanta is a major pediatric health system in Georgia that provided patient samples for the study.
Georgia Tech
The Georgia Institute of Technology is a public research university in Atlanta that collaborated on the GradientScreen technology.
The details
GradientScreen is a microfluidic assay that exposes a patient's leukemia cells to three-drug combinations and measures how many cancer cells survive. It compares responses to single drugs against combinations to identify effective drug combinations and ratios across the full range of ratios in a single experiment.
Timeline
Each year, about 6,000 new acute lymphoblastic leukemia cases are diagnosed in the U.S., including more than 3,500 in children.
GradientScreen is designed to identify a predicted response to treatment at the time of diagnosis.
Health Landscape
The development fits a broader push to match leukemia therapy to individual patients rather than relying on standard regimens. Its planned expansion to acute myeloid leukemia and adult patients would extend that approach to a population where roughly 50% experience relapse or refractory disease.
For families facing a leukemia diagnosis, a tool that anticipates how a child may respond to treatment could inform decisions about drug combinations from the start. Whether it reaches clinics depends on further validation beyond this early retrospective study.
The takeaway
Targeted testing of a patient's own leukemia cells may one day help clinicians choose treatment before side effects and relapse become the outcome. Readers tracking cancer care should watch for prospective studies that confirm these early findings.
What happens next
Initial next steps may include expanding GradientScreen to acute myeloid leukemia and to adult as well as pediatric patients, and establishing it within the Emory Lab for Innovative Assay Development.
Further reading
For more on related research, explore Cancer coverage on Wisevoter.
Source note: This article includes information reported by Emory.






